BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $19
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has initiated coverage on Prime Medicine (NASDAQ:PRME) with an Outperform rating and a price target of $19.
October 09, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prime Medicine has received an Outperform rating from BMO Capital, with a price target of $19.
The Outperform rating from BMO Capital indicates that the analyst expects Prime Medicine to do better than the market average. This positive outlook, coupled with a price target of $19, suggests potential upside for the stock, which could positively impact its short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100